Golenbock Eiseman Assor Bell & Peskoe, LLP
711 Third Avenue – 17th Floor
New York, New York 10017
212-907-7300
Andrew D. Hudders
212-907-7349
ahudders@golenbock.com
October 27, 2021
Securities
and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: Jordan Nimitz, Esq. – Office of Life Sciences
| RE: | TC BioPharm (Holdings) Limited |
| Registration Statement No. 333-260492 | |
| Amendment No 1 to the Registration Statement | |
| on Form F-1, filed on October 26, 2021 |
Dear Ms. Nimitz:
TC BioPharm (Holdings) Limited (the “Company”) is filing today an Amendment No. 1, to its registration statement filed on October 26, 2021, to adjust patient trial information included on pages 75 and 76 of the prospectus with data recently provided the Company from the trial hospital. The Company believes the additional information should be added to the table so that investors may have all the information available to the Company.
If there are any questions concerning the above, please contact either the Company representatives or the undersigned at ahudders@golenbock.com or 212-907-7349.
| Very truly yours, | |
| /s/ Andrew D. Hudders | |
| Andrew D. Hudders |
| cc: | Martin Thorp, TC BioPharm Limited |
| Toby Rintoul, TC BioPharm Limited | |
| Joseph Lucosky, Lucosky Brookman LLP |